Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback